Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine-phospholipid/albumin composite nanoparticles and preparation technology

A technology of albumin and nanoparticles, which can be used in drug combinations, antineoplastic drugs, and pharmaceutical formulations. It can solve problems such as protein structure and function changes, achieve high encapsulation efficiency, increase stability, and avoid direct contact.

Active Publication Date: 2018-03-06
上海乐土生命科技有限公司
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Through investigation, it is found that the existing technology has the following deficiencies: the preparation process of albumin-bound paclitaxel nanoparticles (Abraxane) involves the use of organic solvents, and direct contact between albumin and organic solvents may lead to changes in protein structure and function
There is no report on the preparation method of nanoparticles that does not involve the use of organic solvents; at the same time, there is no study on the effect of pH value on the drug loading and particle size of nanoparticles

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine-phospholipid/albumin composite nanoparticles and preparation technology
  • Medicine-phospholipid/albumin composite nanoparticles and preparation technology
  • Medicine-phospholipid/albumin composite nanoparticles and preparation technology

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Embodiment 1 The preparation technology of a kind of paclitaxel-phospholipid / albumin composite nanoparticle provided by the present invention, its steps are as follows: (1) configure paclitaxel, lecithin, cholesterol and DSPE-PEG 2000 Stock solution; (2) preparing paclitaxel liposome; (3) preparing BSA stock solution; (4) preparing paclitaxel-phospholipid / albumin composite nanoparticles; specifically as follows:

[0036] Prepare 20.4 mg / mL (0.0003 mol / L) albumin stock solution with 0.01 mol / L buffer solution with different pH respectively. Prepare 10mg / mL (0.0117mol / L) paclitaxel, 15.5mg / mL (0.04mol / L) cholesterol, 29.2mg / mL (0.04mol / L) lecithin, 5.6mg / mL (0.002 mol / L) of DSPE-PEG 2000 stock solution;

[0037] Paclitaxel, cholesterol, lecithin, DSPE-PEG 2000 The stock solution was added in a certain proportion to the constantly stirring blank buffer solution at 55°C, stirred for 30 minutes after the addition, and the ethanol was removed by rotary evaporation; the pac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
wavelengthaaaaaaaaaa
angleaaaaaaaaaa
Login to View More

Abstract

The invention provides medicine-phospholipid / albumin composite nanoparticles and a preparation technology. The preparation technology comprises the following steps: (1) preparing paclitaxel, phospholipid, cholesterol and a DSPE-PEG2000 (Distearoyl Phosphoethanolamine-Polyethylene Glycol 2000) stock solution; (2) preparing a paclitaxel liposome; (3) preparing albumin (BSA) stock solution; and (4) preparing the paclitaxel-phospholipid / albumin composite nanoparticles. The preparation method provided by the invention is simple and the problem that the solubility of a difficult-to-dissolve medicinein water is poor can be solved; and a preparation does not contain Cremophor EL and a toxic or side effect caused by a solubilizer in an injection process is avoided. Being different from common liposomes and albumin nanoparticles, the medicine-phospholipid / albumin composite nanoparticles prepared by the preparation technology have the characteristics that DSPE-PEG2000 is added into a prescription so that the stability of the nanoparticles is increased; and the encapsulation efficiency is high, the grain diameter is small and uniform, and the grain diameter of the nanoparticles is not obviously changed after the nanoparticles are stored at room temperature for two weeks.

Description

technical field [0001] The invention belongs to the technical field of biopharmaceuticals, and in particular relates to a drug-phospholipid / albumin composite nanoparticle and a preparation process. Background technique [0002] Paclitaxel (PTX), as one of the hottest new anticancer drugs after adriamycin, is of great significance in the field of tumor-related treatment. Paclitaxel is a kind of diterpenoid compound with excellent anticancer effect extracted from Taxus genus plants such as Pacific yew. The anti-cancer mechanism of paclitaxel is to promote extremely stable microtubule aggregation while blocking the normal physiological depolymerization of microtubules (in the G2 and M phases of the cell division cycle), thereby leading to cell death and hindering tumor growth. purpose of growth. Currently widely used in non-small cell tumors, ovarian cancer, breast cancer, prostate cancer and so on. However, the solubility of paclitaxel in water is extremely low (about 0.658...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/14A61K9/127A61K47/42A61K47/24A61K31/337A61P35/00G06F19/12
Inventor 蔡畅刘敏赵燕娜韩军
Owner 上海乐土生命科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com